Products Xalacom
Xalacom Phase 3 Completed 📈 Rising Glaucoma, Open-Angle, Ocular Hypertension
About Xalacom Xalacom is a phase 3 stage product being developed by Pfizer for Glaucoma, Open-Angle. The current trial status is completed. This product is registered under clinical trial identifier NCT00150267. Target conditions include Glaucoma, Open-Angle, Ocular Hypertension.
Clinical Trials (3) NCT ID Phase Status Start Completion Indication NCT00801437 Pre-clinical Completed Oct 1, 2008 Jun 1, 2009 Glaucoma, Open-angle NCT00143208 Approved Completed May 1, 2003 Apr 1, 2006 Glaucoma NCT00150267 Phase 3 Completed Feb 1, 2002 — Glaucoma, Open-Angle
Product Company Stage Hype Score Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Mankind Pharma Phase 3 Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Eybelis ophthalmic solution 0.002% Santen Pharmaceutical Approved STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 Latanoprost + tafluprost Santen Pharmaceutical Pre-clinical DE-117B Eye Drops + Latanoprost Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution + Timolol ophthalmic solution 0.5% + Placebo ophthalmic solution Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 DE-117 + Latanoprost ophthalmic solution Santen Pharmaceutical Phase 3 DE-117 ophthalmic solution + Timolol ophthalmic solution Santen Pharmaceutical Phase 3 A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL Santen Pharmaceutical Phase 3 Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 2/3
Other Products from Pfizer